Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the results and potential impact from the phase 3 CEPHEUS trial.

One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...

The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed ...

Medically reviewed by Doru Paul, MD Multiple myeloma is a type of blood cancer that develops in plasma cells, a type of white ...

Researchers identified a six-gene pattern predicting venetoclax response in multiple myeloma. This genetic insight allows for ...

Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of ...

That was the only conversation.”The diagnosisThomas suffered from severe back pain for months before being diagnosed with ...

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...

Researchers sought to determine whether PRD monitoring would be a suitable replacement for MRD in multiple myeloma.

A quadruplet regimen is now the preferred first-line treatment for multiple myeloma in both transplant-eligible and ...

The ASH Research Collaborative (ASH RC), a non-profit organization established by the American Society of Hematology (ASH) to improve the lives of those affected by blood diseases, will present new ...

Adaptive Biotechnologies (ADPT) announced that its next-generation sequencing-based clonoSEQ test for measurable residual disease assessment ...